BR112019024717A2 - nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas - Google Patents

nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas Download PDF

Info

Publication number
BR112019024717A2
BR112019024717A2 BR112019024717A BR112019024717A BR112019024717A2 BR 112019024717 A2 BR112019024717 A2 BR 112019024717A2 BR 112019024717 A BR112019024717 A BR 112019024717A BR 112019024717 A BR112019024717 A BR 112019024717A BR 112019024717 A2 BR112019024717 A2 BR 112019024717A2
Authority
BR
Brazil
Prior art keywords
ultra
methods
zirconium
small nanoparticles
tumor
Prior art date
Application number
BR112019024717A
Other languages
English (en)
Inventor
Chen Feng
Ma Kai
S Bradbury Michelle
Wiesner Ulrich
Original Assignee
Univ Cornell
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Memorial Sloan Kettering Cancer Center filed Critical Univ Cornell
Publication of BR112019024717A2 publication Critical patent/BR112019024717A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a nanossondas compreendendo nanopartículas marcadas com zircônio-89 (89zr) ultrapequenas aminadas e conjugadas a crgdy e métodos de sua utilização. as composições proporcionadas são elimináveis por via renal e possuem meia-vida de circulação sanguínea adequada, alta capacidade de direcionamento ativo para o tumor, clearance renal dominante, baixa acumulação no fígado, e uma alta proporção tumoral para segundo plano. as nanossondas descritas apresentam grande potencial como traçadores de "alvo ou livre" ("target-or-clear") para sujeitos humanos para diagnóstico por imagem direcionada sistêmico (ou tratamento) do câncer.
BR112019024717A 2017-05-25 2018-05-17 nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas BR112019024717A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762510859P 2017-05-25 2017-05-25
PCT/US2018/033098 WO2018217528A1 (en) 2017-05-25 2018-05-17 Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof

Publications (1)

Publication Number Publication Date
BR112019024717A2 true BR112019024717A2 (pt) 2020-06-09

Family

ID=62528857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024717A BR112019024717A2 (pt) 2017-05-25 2018-05-17 nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas

Country Status (9)

Country Link
US (1) US11559591B2 (pt)
EP (1) EP3634500B1 (pt)
JP (1) JP2020520953A (pt)
CN (1) CN110869057A (pt)
AU (1) AU2018271781A1 (pt)
BR (1) BR112019024717A2 (pt)
CA (1) CA3064253A1 (pt)
IL (1) IL270777A (pt)
WO (1) WO2018217528A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105307687A (zh) 2013-03-15 2016-02-03 索隆-基特林癌症研究协会 多模态的基于二氧化硅的纳米粒子
CA2980462C (en) * 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
KR20180012299A (ko) 2015-05-29 2018-02-05 메모리얼 슬로안-케터링 캔서 센터 초소형 나노입자를 사용하여 페로토시스를 통해 영양분-결핍 암 세포의 세포 사멸을 유도하는 치료 방법
WO2018213851A1 (en) 2017-05-19 2018-11-22 Cornell University Functionalized nanoparticles and methods of making and using same
EP3634500B1 (en) 2017-05-25 2023-10-25 Memorial Sloan-Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
EP3897752A1 (en) * 2018-12-17 2021-10-27 Memorial Sloan Kettering Cancer Center Inducing favorable effects on tumor microenvironment via administration of nanoparticle compositions
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用
CN114073780A (zh) * 2020-08-21 2022-02-22 上海交通大学 含有放射性金属核素的金属纳米簇、纳米材料及其制备方法和在制备靶向药物中的应用
JP7349578B2 (ja) 2020-10-27 2023-09-22 エルシダ オンコロジー， インコーポレイテッド 葉酸受容体に標的化されたナノ粒子薬物コンジュゲートおよびその使用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
CN114107191B (zh) * 2021-12-09 2024-03-12 益诺思生物技术南通有限公司 一种89Zr标记人脐带间充质干细胞的方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870791A (en) 1972-04-24 1975-03-11 Heskel M Haddad Solid state ophthalmic medication delivery method
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4136177A (en) 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4688506A (en) 1985-09-03 1987-08-25 Breems Martinus Van Boat sail control system
US4788603A (en) 1985-10-19 1988-11-29 Fuji Photo Film Co., Ltd. Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US4713224A (en) 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
KR100612161B1 (ko) 1997-08-15 2006-08-14 세파론, 인코포레이티드 전립선암 치료를 위한 티로신 키나아제 억제제 및 화학적거세법의 조합
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
WO1999037814A1 (en) 1998-01-22 1999-07-29 Luminex Corporation Microparticles with multiple fluorescent signals
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US20030219785A1 (en) 2002-02-01 2003-11-27 Vanderbilt University Targeted drug delivery methods
US8620410B2 (en) 2002-03-12 2013-12-31 Beth Israel Deaconess Medical Center Multi-channel medical imaging system
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
WO2004108902A2 (en) 2003-06-04 2004-12-16 Visen Medical, Inc. Biocompatible fluorescent silicon nanoparticles
US20060173362A1 (en) 2004-10-08 2006-08-03 The Cleveland Clinic Foundation And Vanderbilt University Methods of medical imaging using quantum dots
US7653427B2 (en) 2004-11-12 2010-01-26 Intra-Medical Imaging LLC Method and instrument for minimally invasive sentinel lymph node location and biopsy
US20090110633A1 (en) 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
RU2007138027A (ru) 2005-03-14 2009-04-20 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) Биоактивные пептиды fus-1 и комплексы полипептидов с наночастицами
US8084001B2 (en) 2005-05-02 2011-12-27 Cornell Research Foundation, Inc. Photoluminescent silica-based sensors and methods of use
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
EP1893245A4 (en) 2005-06-24 2009-06-24 Univ Pennsylvania RADIOACTIVELY MARKED PEGYLATION OF LIGANDS FOR USE AS A CONTRAST
FR2888753B1 (fr) 2005-07-21 2008-04-04 Commissariat Energie Atomique Vecteur cible avec fonction d'imagerie activable
US9913917B2 (en) 2005-12-22 2018-03-13 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2008044138A1 (en) 2006-10-12 2008-04-17 Syddansk Universitet Optical nanosensor for detection of reactive oxygen species
US8838213B2 (en) 2006-10-19 2014-09-16 The General Hospital Corporation Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample, and effecting such portion(s)
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
AU2007333225B2 (en) 2006-12-08 2014-06-12 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US20080255460A1 (en) 2007-04-13 2008-10-16 Ethicon Endo-Surgery, Inc. Nanoparticle tissue based identification and illumination
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
WO2009029870A2 (en) 2007-08-31 2009-03-05 Hybrid Silica Technologies, Inc. Peg-coated core-shell silica nanoparticles and methods of manufacture and use
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
WO2009064964A2 (en) 2007-11-15 2009-05-22 The University Of California Switchable nano-vehicle delivery systems, and methods for making and using them
EP4060327A1 (en) 2007-12-21 2022-09-21 President and Fellows of Harvard College Sub-diffraction limit image resolution in three dimensions
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
ES2700870T3 (es) 2009-04-15 2019-02-19 Univ Cornell Nanopartículas de sílice fluorescentes mejoradas a través de densificación de sílice
US9005575B2 (en) 2009-06-12 2015-04-14 Stc.Unm Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
PL2449379T3 (pl) * 2009-07-02 2017-12-29 Sloan-Kettering Institute For Cancer Research Fluorescencyjne nanocząstki na bazie krzemionki
EA201290506A1 (ru) 2009-12-16 2013-03-29 Брихэм Энд Уимен'З Хоспитал, Инк. Частицы для доставки множества агентов
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
GB201121288D0 (en) 2011-12-12 2012-01-25 Univ Muenster Wilhelms Functionalised silicon nanoparticles
US9006987B2 (en) 2012-05-07 2015-04-14 Lighting Science Group, Inc. Wall-mountable luminaire and associated systems and methods
EP2863952B1 (en) 2012-06-22 2018-09-12 Cornell University Mesoporous oxide nanoparticles and methods of making and using same
US9695133B2 (en) 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
ES2709886T3 (es) 2013-02-20 2019-04-22 Univ Cornell Nanopartículas fluorescentes multicapa y procedimientos de fabricación y uso de las mismas
CN105307687A (zh) 2013-03-15 2016-02-03 索隆-基特林癌症研究协会 多模态的基于二氧化硅的纳米粒子
CN113349707A (zh) 2013-12-31 2021-09-07 纪念斯隆-凯特琳癌症中心 用于荧光源实时多通道成像的系统、方法和设备
WO2015183882A1 (en) * 2014-05-29 2015-12-03 Memorial Sloan Kettering Cancer Center Nanoparticle drug conjugates
US10799604B2 (en) 2014-07-25 2020-10-13 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
EP3029032A1 (en) 2014-12-05 2016-06-08 Centre National de la Recherche Scientifique (CNRS) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
CN107249647A (zh) 2014-12-15 2017-10-13 纪念斯隆-凯特琳癌症中心 具有增强的神经结合选择性的环状肽、与所述环状肽结合的纳米颗粒和此二者用于实时体内神经组织成像的用途
CA2980462C (en) 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
EP3291840A4 (en) 2015-05-04 2019-01-02 Cornell University Ultrasmall nanoparticles and methods of making and using same
KR20180012299A (ko) 2015-05-29 2018-02-05 메모리얼 슬로안-케터링 캔서 센터 초소형 나노입자를 사용하여 페로토시스를 통해 영양분-결핍 암 세포의 세포 사멸을 유도하는 치료 방법
US20180296595A1 (en) 2015-09-11 2018-10-18 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer treatment
EP3548096A1 (en) 2016-11-30 2019-10-09 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
US20200155710A1 (en) 2017-04-10 2020-05-21 Cornell University Sulfur- or heavy atom-containing nanoparticles, methods of making same, and uses thereof
WO2018213851A1 (en) 2017-05-19 2018-11-22 Cornell University Functionalized nanoparticles and methods of making and using same
US20200138829A1 (en) 2017-05-24 2020-05-07 Ferro Therapeutics, Inc. Methods of cancer treatment
EP3634500B1 (en) 2017-05-25 2023-10-25 Memorial Sloan-Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
WO2018237253A1 (en) 2017-06-23 2018-12-27 Memorial Sloan Kettering Cancer Center METHOD FOR IN VIVO TISSUE IMAGING USING NANOPARTICLES COMPRISING REFERENCE DYE AND SENSOR COLOR
WO2019113004A1 (en) 2017-12-04 2019-06-13 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis

Also Published As

Publication number Publication date
AU2018271781A1 (en) 2019-12-12
US20200101180A1 (en) 2020-04-02
EP3634500B1 (en) 2023-10-25
WO2018217528A1 (en) 2018-11-29
EP3634500A1 (en) 2020-04-15
US11559591B2 (en) 2023-01-24
CN110869057A (zh) 2020-03-06
IL270777A (en) 2020-01-30
JP2020520953A (ja) 2020-07-16
CA3064253A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
BR112019024717A2 (pt) nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas
Dummer et al. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
Nahrendorf et al. Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct
Liu et al. Hands-free, wireless goggles for near-infrared fluorescence and real-time image-guided surgery
Cohen et al. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets
EA202090776A1 (ru) Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
Polom et al. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green–human serum albumin in comparison with gamma emitting radioactive colloid tracer
BRPI0811210A2 (pt) Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica.
BRPI0512209A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens de um corpo humano ou de animal por formação de imagem óptica, e de monitoração do efeito de tratamento de um corpo humano ou de animal com uma droga para combater uma condição associada com angiogênese
CO2021015520A2 (es) Combinación de marcador de mirna y kit para el diagnóstico del cáncer gástrico
BRPI0606171A2 (pt) agentes para monitoramento da eficácia da terapia e obtenção de imagem de tecido profundo
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
Welling et al. Fluorescent imaging of bacterial infections and recent advances made with multimodal radiopharmaceuticals
WO2015173841A3 (en) Echo-scintigraphic probe for medical applications and relevant diagnostic method
NZ710436A (en) Biospecific agents for bone
Van Iersel et al. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study
MY197419A (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
DK1499584T3 (da) Forbindelser til tumorbilleddannelse
BR112015027249A2 (pt) método de diagnóstico de câncer
Hosseini et al. Fluorescent-tilmanocept for tumor margin analysis in the mouse model
Achilefu Rapid response activatable molecular probes for intraoperative optical image‐guided tumor resection
Liu et al. A non-intrusive evaluation method for tumor-targeting characteristics of nanomedicines based on in vivo near-infrared fluorescence imaging
EA202091767A1 (ru) Новый способ получения визуализирующего соединения
Aydin et al. Intense FDG uptake on PET/CT in the upper and lower respiratory system indicative of Wegener's granulomatosis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]